How can we help?


Bioneer assists clients in the pre-clinical and early clinical phases with production of recombinant proteins in a variety of mammalian cell systems, with access to existing or development of novel functional assays based upon mammalian cells as well as general technology development, e.g. bioreactor evaluation, biobanking, and cell handling. In fact, we can support our clients in the entire process of bringing a novel biologic compound from the laboratory through pre-clinical evaluation for functionality and safety.


Bioneer offers evaluation of compounds using mainly three cell systems 1) Primary dendritic cells (human and murine) 2) Peripheral blood mononuclear cells (PBMCs) and 3) cell line based models. We provide services in our model systems in the discovery process (mainly evaluation of mechanism of action and immune modulation and suppression of specific inflammatory responses) as well as activities involved in the development process (mainly evaluation of safety of IV administered drugs, and assessment of potency).


Bioneer addresses a client's needs for limited amounts of recombinant proteins, e.g. during the discovery phase and preclinical phase of biologics development.


Turning an active compound into a drug product

Pharmaceutical services, covering the field from lead identification to final formulation of the active compound, are provided by Bioneer:FARMA.

Bioneer:FARMA is a business unit of Bioneer established in collaboration with the Faculty of Pharmaceutical Sciences (FARMA), University of Copenhagen, Denmark.


Bioneer offers a range of services related to the identification, validation and documentation of disease relevant biomarkers and drug targets. These services comprise a toolbox of molecular methods that will facilitate the pre-clinical development of both biomarkers, drug-targets and active compounds, which will be useful in diagnostic, prognostic, and therapeutic contexts, and, furthermore, serve as effective means to optimize clinical trial designs.


The Dynamic Gastric Model is the first true "dynamic" in-vitro model of the human stomach that fully replicates the complex biochemical conditions and the array of gastric forces crucial for the prediction of oral pharmaceuticals and food products


Bioneer publishes new article together with Herlev Hospital: microRNA-21 / miR-21 expression in HER2-positive breast cancer and treatment with trastuzumab.
Bioneer publishes new article in Frontiers in Oncology.
Read more
Bioneer publishes article
Bioneer publishes article in Brain Structure and Function.
The title is: DUF1220 protein domains drive proliferation in human neural stem cells and are associated with increased cortical volume in anthropoid primates.
Read more
Read ALL news

Ongoing inNovation consortia:

A Danish initiative to enhance our understanding of the complexity of cancer diseases.
Read more

Meet us at:

ISSCR 12th Annual Meeting in Vancouver, Canada
Bioneer will participate and present at the annual ISSCR meeting, which will be held in Vancouver from June 18-21, 2014.
ISSCR (International Society for Stem Cell Research).
Read more
Scandinavian Neuropathological Society - Annual Meeting
Bioneer will participate and present at the Annual Neuropathological Society meeting held in Copenhagen from the 22-23 of May.
Read more
AACR annual meeting in San Diego, USA
Bioneer will participate and present at the AACR Annual Meeting held in San Diego from the 4-9 of April 2014.
Read more
Dansk Patologiselskab - 13-15 March 2014
Bioneer will participate and present at the annual meeting at Danish Pathological Society, held i Helsingoer from the 13-15 of March 2014.
Read more
Other places to meet us